TwoXAR
Private company
TWOXAR
The convergence of big data, cloud computing, and artificial intelligence has allowed twoXAR to build a drug discovery platform that is order of magnitudes faster, cheaper, and more accurate than traditional wet-lab based approaches.
twoXAR leverages its technology internally to build its own pipeline of therapeutic candidates across diseases as well as collaborate with biotechnology and pharmaceutical companies to jointly discover and develop novel drug candidates by:
- Screening compound libraries for efficacy against a disease or list of diseases
- Screening compound libraries for efficacy against a disease or list of diseases
- Identifying biologic targets from the elucidation of novel biology
2014
Private company
United States of America based
$14.300 M
http://www.twoxar.com/
3
Business model
- Operations Service
Therapeutic focus
- Dermatology
Research focus
- Biology research (Target identification/validation)
Investing history
| 2018 | Series A | 10.0 |
| 2015 | Seed round | 0.9 |
| 2015 | Seed round | 3.4 |
Press releases
No mentions found
Posts Mentioning This Company
Products
No products posted yet
Services
No services posted yet
Clinical Trials
No clinical trials found
Patents/applications
No patents found
Publications (PubMed)
- 31988426 (from 2020-01-29), Author Correction: Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver.
- 31844325 (from 2019-12-18), Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver.
- 27940607 (from 2016-12-13), Synergistic drug combinations from electronic health records and gene expression.
Assets (therapeutic products)
No assets found
| Year | Partner | Focus | Amount of Deal |
|---|---|---|---|
| 2017
(2017, Jan. 1) |
Santen Pharmaceuticals | -- | -- |
